免疫检查点抑制剂相关性肝损伤

详细信息    查看全文 | 推荐本文 |

	英文篇名：Liver injury associated with immune checkpoint blockade 作者：陈瑞玲 ; 马雄 英文作者：CHEN Rui-lin;MA Xiong; 中文刊名：ZUAN 英文刊名：Chinese Hepatology 机构：上海交通大学医学院附属仁济医院上海市消化疾病研究所; 出版日期：2019-02-28 出版单位：肝脏 年：2019 期：v.24 语种：中文; 页：ZUAN201902001 页数：2 CN：02 ISSN：31-1775/R 分类号：5-6

摘要

<正>免疫调节疗法极大地改善了晚期肿瘤转移患者的生存率,已经成为最具前景的新型癌症治疗方法。肿瘤免疫治疗由于其疗效卓越和方法创新,在2013年被Science杂志评为年度十大科学突破之首。免疫检查点抑制剂(immune checkpoint inhibitors, ICIs)是目前肿瘤免疫治疗较成功的领域和研究的热点,并摘得2018年诺贝尔生理学或医学奖。细胞毒性T淋巴细胞相关抗原-4(CTLA-4)、程序性细胞死亡蛋白-1及其配体(PD-1
        

引文

[1] Sanmamed MF, Chen L. A paradigm shift in cancer immunotherapy: From enhancement to normalization. Cell, 2018,175:313-326.
    [2] De Martin E, Michot JM, Papouin B, et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J hepatol, 2018,68:1181-1190.
    [3] Reddy HG, Schneider BJ, Tai AW. Immune checkpoint inhibitor-associated colits and hepatitis. Clin Transl Gastroenterol, 2018,9:180.
    [4] LoPiccolo J, Brener MI, Oshima K, et al. Nodular regenerative hyperplasia associated with immune checkpoint blockade. Hepatology, 2018,68:2431-2433.
    [5] Wanless IR. Micronodular transformation (nodular regenerative hyperplasia) of the liver: A report of 64 cases among 2,500 autopsies and a new classification of benign hepatocellular nodules. Hepatology, 1990,11:787-797.
    [6] Vuppalanchi R, Mathur K, Pyko M, et al. Liver stiffness measurements in patients with noncirrhotic portal hypertension-the devil is in the details. Hepatology, 2018,68:2438-2440.
    [7] Dhanasekaran R, Kwo PY. The liver in oncology. Clin Liver Dis, 2017,21:697-707.